Our TB research at The Union World Conference on Lung Health 2024
11 Nov 2024
This week, researchers from around the world will gather for The Union World Conference on Lung Health, held from 12-16 November in Bali, Indonesia.
Researchers from the MRC Clinical Trials Unit at UCL and our collaborators from other institutions will present our latest tuberculosis (TB) work, including new findings from the TB-CHAMP, TRUNCATE-TB and SURE trials, as well as research exploring subclinical TB, TB screening, and the role of socioeconomic status in multidrug-resistant TB.
Details of the presentations are summarised below. All times are WITA. We will be posting from MRC CTU at UCL social media using the hashtag #UnionConf2024.
Oral sessions
| Day | Time | Session | Title | Presenter |
| Wednesday 13 November |
14:20 | Identification and management of TB infection |
Treatment adherence to an adult levofloxacin formulation in children on multi-drug-resistant TB preventative treatment within the TB-CHAMP trial |
Trinh Duong |
|
Safety profile of levofloxacin preventative treatment for multi-drug-resistant TB: A meta-analysis of the VQUIN and TB-CHAMP trials |
Trinh Duong | |||
| 16:10 | Subclinical TB: How important is it? | What is known about subclinical TB? | Hanif Esmail | |
| Thursday 14 November | 09:20 | The sleeper must not awaken: Detecting and preventing TB | Chair | Hanif Esmail |
| Friday 15 November | 14:20 | Subclinical TB: How far and deep should we go? How do we find subclinical TB and what do we do about it? | Chair | Hanif Esmail |
| Saturday 16 November | 10:20 | "Double Trouble": Addressing the epidemiological and treatment challenges of diabetes and TB | Sensitivity and Specificity of Tuberculosis Screening Tools in People with Diabetes | Neha Janrode |
| 12:40 | Biomarker studies in the TRUNCATE-TB trial: identifying people who can stop treatment after 8 weeks with low risk of relapse | RNA transcriptome biomarkers | Mahdad Noursadeghi | |
| 12:40 | Mtb infection – what we know, what we don’t know and what should we know? | Chair | Hanif Esmail |
Posters
| Day | Time | Session | Title | Presenter |
| Wednesday 13 November | 13:20 | Align cases demand under cost perspective |
Socioeconomic status of households containing children exposed to multi-drug-resistant TB in South Africa |
Thomas Wilkinson |
| Thursday 14 November | 12:15 | Fundamental advances in understanding pathogenesis |
Systemic MMP-8 RNA expression upregulated in children with TB meningitis and associated with infarcts and hydrocephalus |
Julie Huynh |
| Friday 15 November |
09:05 | Mechanisms underlying heterogenous disease manifestations | Single gene transcripts for subclinical TB: An individual participant data meta-analysis | James Greenan-Barrett |
| 12:15 | Treating and preventing drug-resistant TB: Dispatches from the coal face |
Acceptability of an adult levofloxacin formulation in children on multi-drug-resistant TB preventive treatment: A quantitative analysis |
Susan Purchase | |
| 17:45 | Pharmacological considerations for optimising new regimens |
Intensified treatment of tuberculous meningitis in children: First pharmacokinetic data from the SURE trial |
Rob Aarnoutse |
Further information: